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LETTER TO THE EDITOR
Sprue-Like Enteropathy
Associated with Olmesartan:
We  would  like  to  emphasize  the  clinical  relevance
of  this  topic  regarding  its,  until  recently,  unrecognizedAn  Unrecognized Emerging
Drug-Induced Enteropathy?
Enteropatia Sprue-Like Associada com o
Olmesartan: Uma Enteropatia Induzida por
Fármaco Emergente e  Sub-Diagnosticada?
Dear  Editors,
We  read  with  great  interest  the  case  reports  by  da  Silva
et  al.1,  Carneiro  et  al.2 and  Eusébio  et  al.3 published  in  the
late  issue  of  GE  Portuguese  Journal  of  Gastroenterology.
Table  1  Clinical  features  of  two  cases  of  sprue-like  enteropathy  associated  with  olmesartan.  F,  Female;  hypoK,  hipokalemia;
hypoAlb, hypoalbuminemia;  hypoMg,  hypomagnesemia.
Sex  Age  Time  of
diagnosis
Clinical
presentation
Duration  of
symptoms
Laboratorial
ﬁndings
Response  to
eviction  of
olmesartan
Time  of  follow-up
endoscopy/
histology
Resolution  of
histological
changes
F  72  2014  Chronic
diarrhea;
abdominal
discomfort
6  months  Normocytic
anemia;  hypoK;
hypoAlb
Clinical
remission
3  months  Yes
features  and  share  our  small  case-series  experience
(Table  1).
Curiously,  in  both  cases  symptoms  developed  long  (four-
teen  and  ten  months,  respectively)  after  starting  therapy.
This  has  rarely  been  addressed  and  may  difﬁcult  the  diag-
nosis.
The  primary  care  physicians  were  informed  and  advised
to  switch  class  of  medication  in  these  cases.  There  were  no
recurrences  of  symptoms  during  follow-up.F 52  2015  Chronic
diarrhea
4  months  Electroly
abnorma
(severe  h
and  hypo
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6  months  Yes
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